|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006141,
umls-concept:C0008976,
umls-concept:C0010583,
umls-concept:C0013089,
umls-concept:C0015737,
umls-concept:C0018787,
umls-concept:C0018801,
umls-concept:C0021853,
umls-concept:C0085862,
umls-concept:C0205195,
umls-concept:C0231220,
umls-concept:C0243402,
umls-concept:C0282443,
umls-concept:C0332283,
umls-concept:C0543467,
umls-concept:C0677850,
umls-concept:C0680730,
umls-concept:C0728747,
umls-concept:C1299583,
umls-concept:C1511726,
umls-concept:C1518419,
umls-concept:C1522673,
umls-concept:C1524063,
umls-concept:C1549571,
umls-concept:C1552617,
umls-concept:C1608386,
umls-concept:C1709701
|
|
pubmed:issue |
21
|
|
pubmed:dateCreated |
2010-7-19
|
|
pubmed:abstractText |
An independent Adjuvant Cardiac Review and Evaluation Committee (ACREC) systematically reviewed cases of symptomatic heart failure events to uniformly define the cardiac event rate across two large trials (National Surgical Adjuvant Breast and Bowel Project [NSABP] B-31 and North Central Cancer Treatment Group [NCCTG] N9831) that assessed the addition of trastuzumab to standard adjuvant chemotherapy.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
28
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3416-21
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:20530275-Antibodies, Monoclonal,
pubmed-meshheading:20530275-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:20530275-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20530275-Breast Neoplasms,
pubmed-meshheading:20530275-Chemotherapy, Adjuvant,
pubmed-meshheading:20530275-Cyclophosphamide,
pubmed-meshheading:20530275-Doxorubicin,
pubmed-meshheading:20530275-Heart Failure,
pubmed-meshheading:20530275-Humans,
pubmed-meshheading:20530275-Neoplasms,
pubmed-meshheading:20530275-Ventricular Function, Left
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials.
|
|
pubmed:affiliation |
Division of Cardiology, Johns Hopkins Hospital, Baltimore, MD 21287, USA. srusse14@jhmi.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
